The small German biotech firm BioNTech, started by a husband and wife team with Turkish roots, has never brought a vaccine to market before.
But its experimental technology has now put it in pole position in the global race to develop a jab that will end the coronavirus crisis.
Along with its US partner Pfizer, BioNTech announced on Monday that their vaccine has proved 90% effective in ongoing Phase 3 trials, paving the way for them to apply for emergency use approval.
Cance
Mainz-based BioNTech was co-founded in 2008 by Ugur Sahin and his wife Ozlem Tureci, both scientists and the children of Turkish immigrants to Germany, as well as Austrian cancer expert Christoph Huber.
In normal times, BioNTech and its roughly 1,500 employees are focused on developing specialized immunotherapies for cancer patients based on "messenger RNA" (mRNA) molecules that trigger the building of proteins in cells, to stimulate the immune system.
It's this same technology, which has the benefit that it can be developed more quickly than traditional vaccines, that lies at the heart of its Covid-19 shot.
The vaccine would introduce synthetic mRNA into the human body to trick the immune system into producing the viral proteins needed to provoke a safe but robust offensive against the coronavirus.
The company’s shares shot up 23.4% on Monday morning after the Covid-19 vaccine it is developing with the US pharma giant Pfizer became the first candidate worldwide to show positive results in phase 3 trials, the crucial final stage of testing. The total value of BioNTech’s stock is currently $21.9bn, more than four times that of German national carrier Lufthansa and a triumph for a company that only made its debut on the US stock market a year ago, reports the Guardian.
Early in the starting blocks
Sahin, 54, jumped into action in January shortly after reading about the emergence of a new and deadly coronavirus in the Chinese city of Wuhan.
By the time much of the planet was in lockdown in March, BioNTech had developed 20 vaccine candidates based on mRNA technology, he told Der Spiegel weekly.
Those were eventually whittled down to a handful of the most promising options, with vaccine BNT162b2 now becoming the frontrunner.
Teaming up with Pfizer
Having struck a deal with US pharma giant Pfizer to work together to develop mRNA-based flu vaccines in 2018, teaming up on a potential coronavirus vaccine was an obvious next move for BioNTech, which has yet to bring one of its ideas to market.
The two companies announced in March that they aimed to jointly develop a Covid-19 jab, "pairing Pfizer's development, regulatory and commercial capabilities with BioNTech's mRNA vaccine technology and expertise," they said at the time.
While global headlines tend to lead with Pfizer's involvement, Sahin insisted to Spiegel: "It is our technology."
The cooperation is a good fit because it allows BioNTech "to develop and distribute a possible vaccine in the shortest time possible," he added.
In a country where a debate about the willingness of German citizens with Turkish roots to integrate into public life has always been a key issue for the last decade, the story of BioNTech’s founders is ground-breaking.
Tureci and Sahin are children of Turkish Gastarbeiter or “guest workers” who came to Germany in the late 1960s. Sahin was born in southern Turkey but moved to Cologne when he was four. Tureci, the company’s chief medical officer, was born in Lower Saxony, reports the Guardian.
The couple, who hold German citizenship and have a teenage daughter, met at Saarland University in Homburg and have been married since 2002. In an interview with Süddeutsche Zeitung, Türeci said she and her husband started their wedding day in lab coats and resumed their research after a brief dash to the registry office.
The Berlin newspaper Tagesspiegel wrote that their success was “balm for the soul” of Germans with Turkish roots after decades of being stereotyped as lowly educated greengrocers.